Print

Shin Poong Pharmaceutical Co., Ltd. (019170.KS) Seeks US Partners for Hyaluronic Acid Portfolio  
2/25/2013 11:13:22 AM

Seoul, South Korea and San Diego, CA, USA – February 25, 2013 – Shin Poong Pharmaceutical Co., Ltd. (SEO: 019170.KS) announced today that they will attend the BIOCOM Global Life Science Partnering Conference on February 27 – 28 at The Lodge at Torrey Pines in La Jolla, California, and that Shin Poong Pharma is actively seeking commercialization and development partners to address U.S. and international market opportunities for its portfolio of proprietary commercial-stage and development-stage hyaluronic acid specialty product platforms. They will be available to present and discuss an overview of the company and Shin Poong’s portfolio of proprietary hyaluronic acid specialty product platforms.

Shin Poong is currently commercializing its portfolio of HA specialty products in Asia and other international markets. Approved and addressable indications include facial aesthetics, tissue adhesion barriers, and viscosupplementation. A young and growing patent portfolio covers the HA specialty product platforms.

For additional information about Shin Poong’s portfolio of proprietary hyaluronic acid specialty product platforms, please visit www.shinpoongusa.com.

About Shin Poong Pharma

Shin Poong Pharmaceutical Company is a publicly traded company established in 1962 in Seoul, South Korea. It is one of the ten largest pharmaceutical companies in Korea with manufacturing operations in five countries, more than 1,600 employees world-wide, and sales in excess of US $240 million. The company is collaborating with the World Health Organization on the development of a novel anti-malarial drug.

For further information, please visit the website at www.shinpoong.co.kr.

Contact:

Joseph Kozikowski, MD U.S. Medical Director

(858) 350-4288

www.shinpoongusa.com


//-->